Nelmastobart Drug Asset Due Diligence Report 2026

This Nelmastobart Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Nelmastobart can convert its Monoclonal antibody profile and BTN1A1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Nelmastobart (query alias: Nelmastobart)
Modality / target	Monoclonal antibody; BTN1A1; BTN1A1 inhibitors
Highest global status	Phase 2
Originator	STCube, Inc.
Active developers	STCube, Inc., Beijing Weilifang Biotechnology Co., Ltd., SAMSUNG BIOLOGICS Co., Ltd.

The MCP disease footprint includes Recurrent Non-Small Cell Lung Cancer, Head and Neck Neoplasms, Metastatic Colorectal Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07656038	Phase 1	Not yet recruiting	45	Primary endpoint not disclosed in English source
NCT07306624	Phase 2	Recruiting	62	Primary endpoint not disclosed in English source
NCT06873763	Phase 1/2	Recruiting	52	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

BTN1A1 expression as a biomarker for patient selection: Phase 1b IHC analysis and clinical outcomes supporting a biomarker-guided phase 2 trial in colorectal cancer.

Phase 1/2; n=6; evaluation: Positive. Reported fields: BTN1A1 expression(high) = 83.3 %

BTN1A1 and YAP1 expression as biomarkers in colon cancer: Phase 1b trial results of hSTC810

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: Safety = Treatment with hSTC810 demonstrated a favorable safety profile, with the most common adverse events being low-grade fatigue and infusion-related reactions

BTN1A1 expression in colon cancer: Implications for immunotherapy and patient stratification.

Phase 1; n=47; evaluation: Positive. Reported fields: -; ORR = 2.3 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Nelmastobart addresses Recurrent Non-Small Cell Lung Cancer, Head and Neck Neoplasms, Metastatic Colorectal Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: BTN1A1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: BTN1A1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination therapies with BTN1a1 binding proteins and chemotherapeutic agents”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1”. The milestone feed surfaced a patent-application signal described as “Antibodies and molecules that immunospecifically bind to BTN1a1 and the therapeutic uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO